# The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis

> **NCT05689710** · NA · SUSPENDED · sponsor: **Lo.Li.Pharma s.r.l** · enrollment: 30 (estimated)

## Conditions studied

- Metabolic Syndrome
- Cardiac Fibrosis

## Interventions

- **DIETARY_SUPPLEMENT:** Inositol and alpha-lactalbumin

## Key facts

- **NCT ID:** NCT05689710
- **Lead sponsor:** Lo.Li.Pharma s.r.l
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-12-23
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Difficulties in enrollment and patient compliance
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05689710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05689710, "The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05689710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*